Bank Of Montreal Oncolytics Biotech Inc Transaction History

Bank Of Montreal

$214 Billion
Q3 2024

A detailed history of Bank Of Montreal transactions in Oncolytics Biotech Inc stock. As of the latest transaction made, Bank Of Montreal holds 37,924 shares of ONCY stock, worth $35,269. This represents 0.0% of its overall portfolio holdings.

Number of Shares

37,924

Previous 37,425 1.33%

Holding current value

$35,269

Previous $37,000 13.51%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$0.87 - $1.08 $434 - $538	499 Added 1.33%	37,924 $32,000
Q2 2024 Aug 14, 2024	BUY	$0.99 - $1.24 $103 - $130	105 Added 0.28%	37,425 $37,000
Q1 2024 May 13, 2024	SELL	$0.89 - $1.36 $233 - $356	-262 Reduced 0.7%	37,320 $39,000
Q4 2023 Feb 08, 2024	BUY	$1.22 - $2.09 $6,023 - $10,318	4,937 Added 15.12%	37,582 $50,000
Q3 2023 Nov 01, 2023	BUY	$1.98 - $3.24 $524 - $858	265 Added 0.82%	32,645 $71,000
Q2 2023 Aug 02, 2023	SELL	$1.11 - $2.74 $4,973 - $12,277	-4,481 Reduced 12.16%	32,380 $84,000
Q1 2023 Jun 13, 2024	SELL	$1.2 - $1.91 $3,376 - $5,374	-2,814 Reduced 7.54%	34,506 $41,000
Q3 2022 Nov 10, 2022	BUY	$0.98 - $1.51 $4,058 - $6,252	4,141 Added 12.66%	36,861 $50,000
Q2 2022 Aug 11, 2022	SELL	$0.85 - $1.59 $2,550 - $4,770	-3,000 Reduced 8.4%	32,720 $34,000
Q1 2022 May 12, 2022	BUY	$1.31 - $2.02 $6,821 - $10,518	5,207 Added 17.06%	35,720 $58,000
Q4 2021 Feb 11, 2022	BUY	$1.39 - $2.3 $27,774 - $45,958	19,982 Added 189.74%	30,513 $43,000
Q3 2021 Nov 12, 2021	SELL	$1.93 - $2.77 $11,442 - $16,423	-5,929 Reduced 36.02%	10,531 $22,000
Q2 2021 Aug 12, 2021	BUY	$2.6 - $4.64 $42,796 - $76,374	16,460 New	16,460 $46,000

Others Institutions Holding ONCY

# of Institutions

Shares Held

1.18M

Call Options Held

Put Options Held

View Full List

About ONCOLYTICS BIOTECH INC

Ticker ONCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,867,400
Market Cap $53.8M
Description
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a...

More about ONCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.

Account